MKI67 and neoplasm: There were only minor differences in baseline characteristics between patients treated with octreotide versus lanreotide, including a lower median Ki-67 index in patients receiving octreotide (3.3% versus 5%), a higher percentage with hormonal symptoms (69% versus 48%), and a higher fraction with tumor resection (87% versus 67%), see Table 1.